title: Medicine. Hepatitis C can be cured globally, but at what cost?
authors.affiliation: Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3BX, UK. microhaart@aol.com.
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.affiliation: Imperial College London, London SW7 2AZ, UK.
authors.forename: Graham
authors.initials: G
authors.lastname: Cooke
mesh_terms: D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D003906:Developing Countries / Q000191:economics; D016527:Drug Costs / Q000639:trends*; D016568:Drugs, Generic / Q000191:economics / Q000627:therapeutic use; D014943:Global Health; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology*; D006575:Heterocyclic Compounds, 3-Ring / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D000069616:Simeprevir; D000069474:Sofosbuvir; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use; D014542:Uridine Monophosphate / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D016568:Drugs, Generic; D006575:Heterocyclic Compounds, 3-Ring; D013449:Sulfonamides; D000069616:Simeprevir; D014542:Uridine Monophosphate; D000069474:Sofosbuvir